

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Tong Ren Tang Technologies Co. Ltd.

北京同仁堂科技發展股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1666)

VOLUNTARY ANNOUNCEMENT

This announcement is made by the board of directors (the “**Board**”) of Tong Ren Tang Technologies Co. Ltd. (the “**Company**”) on a voluntary basis.

To the best of the directors' knowledge, according to the Notice of China Food and Drug Administration (“**CFDA**”) on 9 Batches of Disqualified Drugs (No. 21 of 2018) issued by CFDA on 26 January 2018, Kaixiong Shunqi Pills (batch number: 15080858) produced by the Company was announced disqualified and the disqualified testing indicator is content uniformity.

The content of Kaixiong Shunqi Pills produced by the Company is 6 gram per bag. The said batch of products was found to be beyond the standard limit in respect of content uniformity in the sampling and inspection of a drug-handling enterprise in Guangxi (the “**Inspected Entity**”) by relevant state drug supervision and inspection authority and was thus decided to be disqualified according to the test results while other test indicators are all qualified. This product will not cause adverse effects and safety risk to the drug users.

Following the thorough investigation on the entire production and sales process of this batch of products conducted by the Company, it is discovered that the disqualified content uniformity was caused by the improper storage by the Inspected Entity. The local drug supervision authority has come to the Company for sampling the retained sample of this batch of products and sent the same to the local drug inspection authority for testing. The test results indicate that the content uniformity is qualified. Meanwhile, the Company also conducted selective test on this batch of products which were sold to other channels and no disqualification of similar kind was found in the test results.

Upholding the attitude of being responsible for consumers, the Company has recalled this batch of products and will fully cooperate with the drug administration authority, and actively take actions to completely avoid the recurrence of such incident.

The sales revenue of Kaixiong Shunqi Pills produced by the Company amounted to approximately RMB13.16 million in 2016, representing 0.28% of the audited revenue of the Group of RMB4,665.30 million in 2016. It is expected that there will be no material change as for the proportion of sales income of the product to the income of the Group in 2017. The Board is of the view that the product recall has no material impact on the normal production and operation of the Company.

By order of the Board
Tong Ren Tang Technologies Co. Ltd.
Gao Zhen Kun
Chairman of the Board

Beijing, the PRC
28 January 2018

As at the date of this announcement, the Board comprises Mr. Gao Zhen Kun, Mr. Gu Hai Ou, Mr. Rao Zu Hai, Mr. Li Bin, Mr. Wang Yu Wei and Ms. Fang Jia Zhi as executive Directors; Miss Tam Wai Chu, Maria, Mr. Ting Leung Huel, Stephen and Mr. Jin Shi Yuan as independent non-executive Directors.